Journal of Antimicrobial Chemotherapy, Vol 40, 639-651, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
A Bauernfeind
The in-vitro activities of the quinolones Bay 12-8039, gatifloxacin (AM
1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin were
compared. Gram-positive cocci were most susceptible to Bay 12- 8039,
clinafloxacin and trovafloxacin; Enterobacteriaceae and fastidious
organisms were most susceptible to clinafloxacin [corrected]; Pseudomonas
spp. were most susceptible to clinafloxacin and ciprofloxacin; anaerobes,
Helicobacter pylori and Campylobacter jejuni were most susceptible to
gatifloxacin, clinafloxacin and trovafloxacin. Against gram-positive cocci,
the only agents that were more active than ciprofloxacin were those
carrying an azabicyclo (trovafloxacin, Bay 12-8039), 3-amino-pyrrolidinyl
(clinafloxacin) or 3- methyl-piperazinyl (gatifloxacin) moiety at position
C7.
ORIGINAL ARTICLES
Comparison of the antibacterial activities of the quinolones Bay 12- 8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [published erratum appears in J Antimicrob Chemother 1998 Jun;41(6):672]
Max von Pettenkofer-Institut, Munich, Germany. Adolf.Bauernfeind@mvp- bak.med.uni-muenchen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. M. Ednie and P. C. Appelbaum Antianaerobic Activity of Sulopenem Compared to Six Other Agents Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2163 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cheng, J. A. Thanassi, C. L. Thoma, B. J. Bradbury, M. Deshpande, and M. J. Pucci Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2445 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishizawa, H. Suzuki, K. Kurabayashi, T. Masaoka, H. Muraoka, M. Mori, E. Iwasaki, I. Kobayashi, and T. Hibi Gatifloxacin Resistance and Mutations in gyrA after Unsuccessful Helicobacter pylori Eradication in Japan. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1538 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hariprasad, G. K. Shah, W. F. Mieler, L. Feiner, K. J. Blinder, N. M. Holekamp, H. Gao, and R. A. Prince Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol, February 1, 2006; 124(2): 178 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lehtopolku, A. J. Hakanen, A. Siitonen, P. Huovinen, and P. Kotilainen In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance J. Antimicrob. Chemother., December 1, 2005; 56(6): 1134 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schaumann, E. J. Goldstein, J. Forberg, and A. C Rodloff Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures J. Med. Microbiol., August 1, 2005; 54(8): 749 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Campion, P. J. McNamara, and M. E. Evans Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus Antimicrob. Agents Chemother., January 1, 2005; 49(1): 209 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hariprasad, K. J. Blinder, G. K. Shah, R. S. Apte, B. Rosenblatt, N. M. Holekamp, M. A. Thomas, W. F. Mieler, J. Chi, and R. A. Prince Penetration Pharmacokinetics of Topically Administered 0.5% Moxifloxacin Ophthalmic Solution in Human Aqueous and Vitreous Arch Ophthalmol, January 1, 2005; 123(1): 39 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peric, M. R. Jacobs, and P. C. Appelbaum Antianaerobic Activity of a Novel Fluoroquinolone, WCK 771, Compared to Those of Nine Other Agents Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3188 - 3192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schaumann, R. Blatz, J. Beer, G. Ackermann, and A. C. Rodloff Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli J. Antimicrob. Chemother., February 1, 2004; 53(2): 318 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liebetrau, A. C. Rodloff, J. Behra-Miellet, and L. Dubreuil In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3667 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Krausse and U. Ullmann In Vitro Activities of New Fluoroquinolones against Campylobacter jejuni and Campylobacter coli Isolates Obtained from Humans in 1980 to 1982 and 1997 to 2001 Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2946 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wagner, M. Jabbusch, M. Eisenblatter, H. Hahn, C. Wendt, and R. Ignatius Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2358 - 2361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince, X. Zhang, and D. C. Hooper Activity of and Resistance to Moxifloxacin in Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1410 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hariprasad, W. F. Mieler, and E. R. Holz Vitreous and Aqueous Penetration of Orally Administered Gatifloxacin in Humans Arch Ophthalmol, March 1, 2003; 121(3): 345 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Fish, M. K. Choi, and R. Jung Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs J. Antimicrob. Chemother., December 1, 2002; 50(6): 1045 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Brown-Elliott, R. J. Wallace Jr., C. J. Crist, L. Mann, and R. W. Wilson Comparison of In Vitro Activities of Gatifloxacin and Ciprofloxacin against Four Taxa of Rapidly Growing Mycobacteria Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3283 - 3285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peric, G. Lin, C. L. Clark, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents J. Antimicrob. Chemother., July 1, 2002; 50(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bassetti, L. M. Dembry, P. A. Farrel, D. A. Callan, and V. T. Andriole Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and {beta}-Lactams against Gram-Positive Clinical Isolates Antimicrob. Agents Chemother., January 1, 2002; 46(1): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Zinner, A. A. Firsov, D. Gilbert, K. Simmons, and I. Yu. Lubenko The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses J. Antimicrob. Chemother., December 1, 2001; 48(6): 821 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Entenza, Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3076 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rodriguez-Cerrato, C. C. McCoig, I. C. Michelow, F. Ghaffar, H. S. Jafri, R. D. Hardy, C. Patel, K. Olsen, and G. H. McCracken Jr. Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3092 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Ross, D. H. Wright, L. B. Hovde, M. L. Peterson, and J. C. Rotschafer Fluoroquinolone Resistance in Anaerobic Bacteria following Exposure to Levofloxacin, Trovafloxacin, and Sparfloxacin in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., July 1, 2001; 45(7): 2136 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lister and C. C. Sanders Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother., June 1, 2001; 47(6): 811 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gales, H. Sader, and R. N. Jones Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999) Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1463 - 1466. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. D. Dresser, M. S. Niederman, and J. A. Paladino Cost-effectiveness of Gatifloxacin vs Ceftriaxone With a Macrolide for the Treatment of Community-Acquired Pneumonia Chest, May 1, 2001; 119(5): 1439 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Xuan, M. Zhong, H. Mattoes, K. Q. Bui, J. McNabb, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale Streptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model Antimicrob. Agents Chemother., March 1, 2001; 45(3): 794 - 799. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Hoellman, L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum Comparative Antianaerobic Activity of BMS 284756 Antimicrob. Agents Chemother., February 1, 2001; 45(2): 589 - 592. [Abstract] [Full Text]
|
|
|
|
|
|
H. F. Geerdes-Fenge, A. Wiedersich, S. Wagner, K.-H. Lehr, P. Koeppe, and H. Lode Levofloxacin Pharmacokinetics and Serum Bactericidal Activities against Five Enterobacterial Species Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3478 - 3480. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. Firsov, I. Yu. Lubenko, S. N. Vostrov, O. V. Kononenko, S. H. Zinner, and Y. A. Portnoy Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses J. Antimicrob. Chemother., November 1, 2000; 46(5): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. G. Sanchez, N. G. Saenz, M. R. Rincon, I. T. Martin, E. G. Sanchez, and M. J. F. Martinez Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones J. Antimicrob. Chemother., August 1, 2000; 46(2): 283 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Heinemann, H. Wisplinghoff, M. Edmond, and H. Seifert Comparative Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Epidemiologically Defined Acinetobacter baumannii Strains Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2211 - 2213. [Abstract] [Full Text]
|
|
|
|
|
|
S. N. Vostrov, O. V. Kononenko, I. Y. Lubenko, S. H. Zinner, and A. A. Firsov Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio Antimicrob. Agents Chemother., April 1, 2000; 44(4): 879 - 884. [Abstract] [Full Text]
|
|
|
|
|
|
D. Milatovic, F.-J. Schmitz, S. Brisse, J. Verhoef, and A. C. Fluit In Vitro Activities of Sitafloxacin (DU-6859a) and Six Other Fluoroquinolones against 8,796 Clinical Bacterial Isolates Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1102 - 1107. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. MacGowan, K. E. Bowker, M. Wootton, and H. A. Holt Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G J. Antimicrob. Chemother., December 1, 1999; 44(6): 761 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pong, K. S. Thomson, E. S. Moland, S. A. Chartrand, and C. C. Sanders Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin J. Antimicrob. Chemother., November 1, 1999; 44(5): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schaumann, G. Ackermann, B. Pless, M. C. Claros, and A. C. Rodloff In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2783 - 2786. [Abstract] [Full Text]
|
|
|
|
|
|
S. Brisse, A. C. Fluit, U. Wagner, P. Heisig, D. Milatovic, J. Verhoef, S. Scheuring, K. Köhrer, and F.-J. Schmitz Association of Alterations in ParC and GyrA Proteins with Resistance of Clinical Isolates of Enterococcus faecium to Nine Different Fluoroquinolones Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2513 - 2516. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Pendland, M. Diaz-Linares, K. W. Garey, J. G. Woodward, S. Ryu, and L. H. Danziger Bactericidal Activity and Postantibiotic Effect of Levofloxacin against Anaerobes Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2547 - 2549. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Postantibiotic Effects of Gatifloxacin against Gram-Positive and -Negative Organisms Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2574 - 2575. [Abstract] [Full Text]
|
|
|
|
|
|
S. Brisse, D. Milatovic, A. C. Fluit, J. Verhoef, N. Martin, S. Scheuring, K. Köhrer, and F.-J. Schmitz Comparative In Vitro Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes Clinical Isolates with Alterations in GyrA and ParC Proteins Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2051 - 2055. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. N. Jones, D. J. Biedenbach, M. E. Erwin, M. L. Beach, M. A. Pfaller, and The Quality Control Study Group Activity of Gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, Including Susceptibility Test Development, E-Test Comparisons, and Quality Control Guidelines for H. influenzae J. Clin. Microbiol., June 1, 1999; 37(6): 1999 - 2002. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Hoellman, G. Lin, M. R. Jacobs, and P. C. Appelbaum Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents J. Antimicrob. Chemother., May 1, 1999; 43(5): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lober, S. Ziege, M. Rau, G. Schreiber, A. Mignot, P. Koeppe, and H. Lode Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and Magnesium Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1067 - 1071. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. Firsov, R. G. Vasilov, S. N. Vostrov, O. V. Kononenko, I. Yu. Lubenko, and S. H. Zinner Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model J. Antimicrob. Chemother., April 1, 1999; 43(4): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. von Eiff and G. Peters Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci J. Antimicrob. Chemother., April 1, 1999; 43(4): 569 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. N. Vostrov, A. A. Shevchenko, Y. A. Portnoy, and S. H. Zinner A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2841 - 2847. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. V. Piddock, M. Johnson, V. Ricci, and S. L. Hill Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2956 - 2960. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum Activities of Gatifloxacin Compared to Those of Seven Other Agents against Anaerobic Organisms Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2459 - 2462. [Abstract] [Full Text]
|
|
|
|
|
|
B. Ji, N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis Antimicrob. Agents Chemother., August 1, 1998; 42(8): 2066 - 2069. [Abstract] [Full Text]
|
|